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INTRODUCTION
Surgery is not free from significant complications, despite 
advancement in surgical techniques and in perioperative care. 
One of the major complications, particularly for breast and soft 
tissues surgery, is post-operative bleeding which represents a 
critical and, in some cases, lethal risk factor [1,2]. Moreover, post-
operative bleeding after breast surgery causes a severe discomfort 
to the patient, entailing the need for surgical re-intervention and 
sometimes blood transfusions. Another frequent complication of 
breast surgery is seroma, which often requires numerous accesses 
for outpatient drainage, finally resulting in a delay of adjuvant 
therapy administration and a significant psychological burden [3].
A recent study conducted in the United States has extracted from 
the 2011 Nationwide Inpatient Sample the hospital discharge 
rates for primary diagnosis of breast cancer and has selectively 
identified discharges with post-operative bleeding [3]. Results 
showed that even if only 2.5% of the discharges had bleeding 
complications and eventually needed re-operation, globally, 
bleeding complications extended the length of stay by 1.3 days 
while increasing hospital costs by $5495 per admission. Moreover, 
even higher health costs and patients’ discomfort are associated 
with the treatment of chronic or refractory seroma [3].
The risk of blood loss or seroma could be limited by identifying 
and then correcting potential triggers, but although this topic has 
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ABSTRACT
Aim: This study aimed to evaluate the benefits of Arnica montana on post-operative blood loss and seroma 
production in women undergoing unilateral total mastectomy by administering Arnica Montana 1000 Korsakovian 
dilution (1000 K). Materials and Methods: From 2012 to 2014, 53 women were randomly assigned to 
A. montana or placebo and were followed up for 5 days. The main end point was the reduction in blood and 
serum volumes collected in drainages. Secondary end points were duration of drainage, a self-evaluation of 
pain, and the presence of bruising or hematomas. Results: The per-protocol analysis revealed a lower mean 
volume of blood and serum collected in drainages with A. montana (−94.40 ml; 95% confidence interval 
[CI]: 22.48-211.28; P = 0.11). A regression model including treatment, volume collected in the drainage on 
the day of surgery, and patient weight showed a statistically significant difference in favor of A. montana 
(−106.28 ml; 95% CI: 9.45-203.11; P = 0.03). Volumes collected on the day of surgery and the following 
days were significantly lower with A. montana at days 2 (P = 0.033) and 3 (P = 0.0223). Secondary end 
points have not revealed significant differences. Conclusions: A. montana 1000 K could reduce post-operative 
blood and seroma collection in women undergoing unilateral total mastectomy. Larger studies are needed 
with different dilutions of A. montana to further validate these data.
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been extensively studied, both hemorrhage and seroma are still 
largely reported [4,5]. Homeopathy could provide remedies based 
on compounds with anti-hemorrhagic and anti-inflammatory 
properties, but their use in diluted homeopathic solutions has 
been poorly investigated [6-9]. Indeed, some homeopathic 
remedies have been already evaluated in various surgical settings, 
however showing controversial effects [10-17]. Arnica montana 
is a plant belonging to the Compositae family and it grows in 
East and Central Europe [18]. In particular, its anti-inflammatory 
action is linked to the lactone helenalin that seems to be involved 
in the inhibition of the pro-inflammatory transcription factor 
nuclear factor kappa B (NF-κβ) [19-27]. A. montana has been 
recently evaluated in several surgical settings such as esthetic and 
orthopedic surgeries, but currently, no single study is available 
in literature on the effects of this homeopathic remedy in breast 
cancer surgery. In the present study, a homeopathic preparation of 
A. montana 1000 Korsakovian dilution (1000 K) was administered 
preoperatively and postoperatively in a placebo-controlled, 
double-blind clinical trial to patients undergoing unilateral total 
mastectomy, with or without reconstruction, to evaluate any 
favorable or adverse effect on post-operative blood and seroma 
collection from surgical drains.
MATERIALS AND METHODS
Study Design
This randomized, double-blind, placebo-controlled study 
was carried out between 2012 and 2014 in a single university 
hospital department (Breast Unit, “Luigi Sacco” University 
Hospital, Milan, Italy). Fifty-three women affected by breast 
cancer who were candidates for unilateral total mastectomy, 
with or without reconstruction, were enrolled in the study. The 
study was authorized by the Ethical Committee of the same 
university hospital (Trial Register number: 93/2011, approved by 
Ethical Committee on February 15, 2012) and was conducted in 
accordance with the International Conference on Harmonization 
of Good Clinical Practice guidelines. Only patients who had 
given written informed consent were considered for inclusion. 
Women were included in the study if they were: (a) aged between 
20 and 75 years; (b) hospitalized for unilateral total mastectomy, 
with or without reconstruction; (c) and subjected to standard 
treatment, as described in the “concomitant therapies” section. 
Other variables, such as weight and breast size, were recorded 
and considered.
Women were excluded from the study if they were: (a) receiving 
complex surgery such as breast reconstruction by transverse 
rectus abdominis or latissimus dorsi myocutaneous flaps, or in 
case of needed axillary dissection; (b) admitted at the emergency 
department; (c) receiving anticoagulants and antiplatelet 
treatments; (d) affected by bleeding disorders; (e) patients with 
liver pathologies or with concomitant severe general diseases; 
(f) patients receiving drug therapy with aromatase inhibitors or 
anticancer therapies; (g) patients with a history of stroke or of 
acute myocardial infarction, <24 months before; (h) patients 
diagnosed with other concurrent tumors; (i) patients who had 
participated in other clinical trials in the 3 months prior to the 
study; (j) and patients with values of prothrombin time (PT), 
partial thromboplastin time (PTT), and fibrinogen outside 
the normal range of the clinical site (i.e., 0.85-1.18 s for PT, 
0.85-1.20 s for PTT, and 170-400 mg/dL for fibrinogen). The 
day before surgery (day 0), vital signs (blood pressure, heart 
rate, and blood oxygen saturation) were evaluated, along with 
any concomitant medication and any adverse event that could 
have occurred since the screening visit. Moreover, based on the 
results of blood tests, the eligibility of the patient was re-verified. 
The enrolled patient was then assigned to a treatment group 
according to the randomization list.
Randomization was created by the Contract Research 
Organization (CRO) Opera S.r.l. and generated using the 
random function (proc plan) of SAS (version 9.4) software. At 
screening, each patient was assigned to a code composed of the 
identification number of the clinical site in two digits (e.g., 01) 
and the identification number of the patient to three digits 
(e.g., 001-002-003). Time and date of each administration were 
recorded. The CRO Opera S.r.l held the key to the randomization 
list in a sealed envelope, which was not opened until the end of 
the study. The key was used only after freezing of the database 
and finalization of the statistical analyses.
The patients, according to the randomization list, received 
sublingually a dose of five drops of A. montana 1000 K 3 times 
a day, or placebo with identical times of administration, from 
1st day before the surgery until the 4th day after the surgery 
(in total 6 days). On the day of surgery (day 1), the previously 
assigned treatment was continued. All the patients were operated 
by the same surgical team. During the operation, surgical drains 
with a caliber of 15 French (equal to 5 mm in diameter) were 
positioned. Surgeons did not know the allocation of patients in 
the treatment groups. From the end of surgery and for every 12 h, 
a control was carried out, the amount of blood and serum volumes 
collected through drainages was recorded, and for every 24 h, a 
blood test for the evaluation of the complete blood count (CBC) 
and the performance of coagulation factors was carried out. In 
the days following the surgery (days 2-4), the patients continued 
the previously assigned treatment. Vital signs, any concomitant 
medication, adverse event, and the presence of bruises or 
hematomas were monitored. Finally, patients were asked to 
provide an opinion on the perception of pain after surgery, using 
a visual analog scale (VAS). Day 5 concluded the study. On this 
day, the treatment previously assigned was continued, and the 
liquid collected by drains (if still positioned) was measured. If 
it was still not possible to remove the drainage, the amount of 
fluid drained was registered for the last time and, based on other 
parameters, the date of the possible discharge of the patient was 
indicatively anticipated. Conversely, if all parameters resulted in 
the normal range and drains were removed, the patient had the 
possibility to be discharged before the 5th day; in this case, the 
patient was not prematurely withdrawn, but she was considered 
having correctly completed the study.
Endpoints
The principal endpoint of the study was the efficacy of 
A. montana versus placebo in reducing the post-operative 
blood loss and seroma production in patients undergoing 
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unilateral total mastectomy, with or without reconstruction. 
The secondary end points included the following:
•	 Duration	of	drainage,	which	was	calculated	from	day	1	to	
the day of drainage removal
•	 Time	to	reach	a	collected	volume	below	10	ml
•	 Self-evaluation	of	pain,	measured	by	VAS	after	surgery
•	 The	average	time	of	hospitalization	after	surgery,	which	was	
measured in days following surgery
•	 The	presence	of	bruising	and	hematomas	or	breast	swelling,	
measured both in terms of presence versus absence and of 
description or size
•	 The	differences	between	the	volume	collected	on	day	1	and	
the volume collected in each of the following days
•	 Possible	adverse	reactions	to	treatment.
Sample Size
The appropriate accrual hypothesized for the study was set to 
60 patients, with a 1:1 ratio per treatment group (A. montana 
1000 K vs. placebo). Considering a possible 10% dropout rate, 
this sample size could allow us to have a final population of 
53 women, presenting a mean blood and serum collection of 
280 ml in the placebo group and of 200 ml in A. montana group 
(SD 100 ml), considering adequate a statistical power equal to 
80%. Finally, 53 women with breast cancer and candidate for 
unilateral total mastectomy, with or without reconstruction, 
were enrolled in the study.
Study Treatment
A. montana 1000 K was in the form of drops in 30% hydro alcoholic 
solution, with sublingual absorption. The 1000 K dilution is a very 
high homeopathic dilution produced according to the French 
Pharmacopoeia, starting from a mother tincture (complete plant 
extract) which undergoes 1000 steps of successive dilution and 
shaking in a 30% water–alcohol solution. The mother tincture of 
the product used in this study contained a minimum content of 
0.04% of sesquiterpenes (expressed as dihydrohelenanin tiglate). 
According to the Korsakovian dilution method, the same flask 
was used for the entire preparation: At each step, the flask was 
emptied of most of the liquid but not dried, and then immediately 
filled again with the solvent. Because the residual volume after 
emptying the flask certainly cannot be >10% of the total used 
in each dilution, the 1000th K dilution is sufficiently high that 
it certainly does not contain toxic amounts of the plant. The 
placebo drops were identical in appearance to the active drops, 
but included only 30% hydro alcoholic solution without any 
homeopathic dilution. The studied homeopathic treatment and 
the placebo were manufactured and supplied in strictly identical 
packaging by Laboratoires Boiron S.r.l. (Segrate, Milan, Italy).
Concomitant Therapies
A standard treatment used in the management of surgical 
procedures was administered to all the patients enrolled in the 
study. In particular, it was provided as follows:
•	 Antibiotic	prophylaxis	with	cefazolin	2	g	intravenous	(IV)	
once;
•	 Antithrombotic	 prophylaxis	 using	 low	molecular	weight	
heparin at a dose of 4000 IU 12 h before the surgery;
•	 Analgesic	therapy	with	paracetamol	1000	mg	IV	for	every	6	
h for the first 24 h and tramadol 100 mg IV, if needed.
For patients undergoing reconstruction, morphine 20 mg 
in continuous infusion with antiemetic medication was 
administered for the first 48 h.
Statistical Analysis
Interval data were described as the number, mean, and standard 
deviation (SD). Ordinal data were described as the absolute and 
relative frequencies with 95% confidence intervals. Comparisons 
of means were carried out by analysis of variance. The differences 
in the blood and serum volumes collected by the drainage 
between A. montana and placebo were evaluated with three 
linear regression models:
•	 Model	1:	Includes	the	treatment;
•	 Model	2:	Includes	the	treatment	and	the	volume	collected	
on the day of the intervention;
•	 Model	3:	Includes	the	treatment,	the	volume	collected	on	
the day of surgery, and patient weight.
Methods of survival analysis (Kaplan–Meier) were used to 
evaluate the duration of drainage need and time to reach a 
collected volume below 10 ml. Survival curves were compared 
using the log-rank test. Quantitative variables were compared 
using Student’s t-test for normal distributions. The level of 
significance was set at 5% (P = 0.05). All statistical analyses 
were carried out using SAS (version 9.4) software.
RESULTS
The 53 women enrolled in the study (26 in the A. montana 
group and 27 in the placebo group) were all included in the 
intention-to-treat (ITT) population, defined as all patients who 
took at least one dose of A. montana 1000 K or placebo. The per-
protocol (PP) population included all women of the ITT dataset, 
except those women violating the protocol. In particular, in the 
A. montana group, three patients were excluded (two had PT, 
PTT, and fibrinogen altered values, and one patient received 
axillary dissection). In the placebo group, seven patients were 
excluded (five had PT, PTT, and fibrinogen altered values, 
and two were on aromatase inhibitor or anticoagulant therapy 
introduced after enrollment). The baseline characteristics of 
the included patients are described in Table 1. There were no 
significant differences between treatment groups.
Blood and serum collected by drainages dramatically increased 
between day 1 and day 2 and then decreased in both treatment 
groups [Figure 1]. In the PP dataset, the collected volumes were 
higher in placebo group, but in the ITT dataset, the difference 
was less noticeable [Figure 1a]. In the PP dataset, the differences 
between the volume collected on day 1 and the volume collected 
in each of the following days revealed a difference steadily lower 
in the A. montana group compared to placebo [Figure 1b]. These 
differences were statistically significantly different between the 
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two treatment groups on day 2, both in the univariate model (P 
= 0.034) and in the model including treatment and collected 
volume (P = 0.033), and on day 3, only in the latter model (P 
= 0.0223) adjusted for weight and volume to the day of surgery. 
The difference between the two treatments was not statistically 
significant on days 4 and 5. Globally, a lower mean volume of 
blood and serum collected by drainage was observed in A. montana 
group compared to placebo (in PP analysis: 334.35 vs. 428.75 ml, 
P = 0.11) [Tables 2 and 3]. A statistically significant difference 
was shown in regression model 3 applied on PP dataset, when the 
estimates were also adjusted for the volume collected from the 
drainage on day 1 and the weight of the patient [Table 4].
During the 5 days of the study, the drainage was removed in 
36 patients, equally distributed in the two groups. The analysis 
of time of drain removal revealed no difference between the 
two groups of patients both in the ITT dataset (log-rank test 
P = 0.7287) and in the PP dataset (log-rank test P = 0.8653), 
although in A. montana group, drainage was apparently removed 
earlier [Figure 2a]. The analysis of the time up to collected 
volume below 10 ml neither revealed difference between the 
two treatments in the ITT analysis (log-rank test P = 0.8653) 
nor in the PP analysis (log-rank test P = 0.6138), but showing 
a better performance of the patients treated with A. montana 
in the latter [Figure 2b].
The presence of bruising and hematomas or breast swelling 
did not differ significantly by treatment group, P = 0.67 and 
P = 0.57, respectively. Even the perception of pain, measured 
by VAS, showed no statistically significant differences between 
the two treatment groups (P > 0.05). All the recorded adverse 
events were not severe (e.g., rush, headache, nausea), not 
correlated with the A. montana treatment, and completely 
recovered at the end of the study. Moreover, they were equally 
distributed between the two groups: Five patients experienced 
at least an adverse event in the A. montana group versus four 
in the placebo group.
DISCUSSION
In this study, which to our knowledge is the first to test the 
effect of A. montana in breast cancer surgery, we have measured 
Table 1: Baseline characteristics of the ITT population
Characteristics Statistics Placebo (N=27) Arnica (N=26)
Age Mean±SD 56.59±12.65 55.77±11.41
Median 52.28 53.60
Min‑Max 33.91‑75.42 38.15‑73.22
Race Asian (%) ‑ 1 (3.8)
Caucasian (%) 27 (100) 25 (96.2)
Height Mean±SD 160.96 (4.74) 162.46 (7.27)
Median 162 160.50
Min‑Max 150‑70 150‑178
Weight Mean±SD 64.19±13.05 66.95±13.17
Median 60.40 62.90
Min‑Max 48.00‑104.50 50.10‑96.30
BMI Mean±SD 24.74±4.71 25.33±4.59
Median 24.34 22.81
Min‑Max 18.25‑40.82 20.04‑38.58
Systolic blood 
pressure (mmHg)
Mean±SD 119.74±17.90 120.00±15.30
Median 120.00 120.00
Min‑Max 85.00‑150.00 100.00‑160.00
Diastolic blood 
pressure (mmHg)
Mean±SD 73.52±11.99 75.19±7.41
Median 70.00 80.00
Min‑Max 50.00‑100.00 60.00‑90.00
Heart rate (beats/min) Mean±SD 73.78±8.45 74.88±11.67
Median 74.00 75.00
Min‑Max 60.00‑88.00 50.00‑102.00
SD: Standard deviation, ITT: Intention‑to‑treat
Table 2: Mean daily volume and total volume in the two 
treatment groups for the ITT dataset
Treatment ITT dataset 95% CI
Day Patients (N) Volume 
Mean (ml)
SD
A. montana 
1000 K N=26
1 26 39.42 40.68 23.79‑55.06
2 26 124.42 49.94 105.23‑143.62
3 26 98.08 57.08 76.14‑120.02
4 25 70.20 65.54 44.51‑95.89
5 20 55.00 97.73 12.17‑97.83
Total 26 371.73 239.97 279.49‑463.97
Placebo
N=27
1 27 37.78 30.21 26.38‑49.17
2 27 133.15 82.38 102.07‑164.22
3 27 107.41 70.39 80.86‑133.96
4 26 71.15 59.02 48.47‑93.84
5 21 49.52 60.09 23.82‑75.23
Total 27 385.37 235.36 296.59‑474.15
SD: Standard deviation, ITT: Intention‑to‑treat, A. montana: Arnica 
montana, CI: Confidence interval
Table 3: Mean daily volume and total volume in the two 
treatment groups for the PP dataset
Treatment PP dataset 95% CI
Day Patients (n) Volume 
mean (ml)
SD
A. montana 
1000 K
N=23
1 23 42.17 40.42 24.70‑59.65
2 23 119.78 45.11 100.27‑139.29
3 23 91.09 50.99 69.04‑113.14
4 22 57.73 35.81 41.85‑73.61
5 18 33.33 37.10 14.88‑51.78
Total 23 334.35 164.64 263.15‑405.55
Placebo
N=20
1 20 43.50 28.43 30.20‑56.80
2 20 154.50 77.15 118.39‑190.61
3 20 127.00 66.34 95.95‑158.05
4 20 67.50 45.67 46.13‑88.87
5 16 45.31 52.87 17.14‑73.48
Total 20 428.75 214.32 328.44‑529.06
SD: Standard deviation, A. montana: Arnica montana, CI: Confidence 
interval, PP: Per‑protocol
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the efficacy of the homeopathic treatment versus placebo in 
reducing the post-operative bleeding and seroma production 
in patients subjected to total mastectomy. The difference in 
the volume of blood and serum collected by drainages between 
the group of women treated with A. montana and those treated 
with placebo was statistically significant in the PP dataset, but 
only in the model which included, in addition to the type of 
treatment, the volume collected on the day of surgery, and 
the weight of the patient. Thus, we determine that these two 
additional variables have a considerable effect on the efficacy 
of the treatment, and further studies are needed to investigate 
their specific contributions. In general, the other data obtained, 
such as a slightly earlier removal of the drainage and a faster 
reduction in the volume of blood and serum collected in the 
drainage, were not statistically significant and only suggested 
a slight advantage in the post-operative recovery process of 
patients treated with A. montana. The variability is similar in 
the two groups and it appears not due to different responses 
to the drug tested. The high Korsakovian dilution used in this 
study compared to other studies could explain the failure to 
reach the threshold of significance despite the fact that the 
differences are quantitatively small but noticeable [6,11]. This 
high Korsakovian dilution was chosen to surely avoid any toxicity 
from A. montana extract, to administer a harmless experimental 
treatment.
Overall, the efficacy of homeopathic treatments in surgical 
settings is still controversial. In obstetrics, evaluating the effect 
of A. montana and Bellis perennis on blood loss, Oberbaum et al. 
found that the mean hemoglobin levels remained the same 
Figure 1: Changes in volume collected by drainage from day 1 to each following day per treatment: (a) Intention-to-treat population and (b) per-
protocol population; *P < 0.05
a
b
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after the administration of the homeopathic treatment whereas 
the levels decreased significantly in the placebo group (12.7 
versus 11.6; P < 0.05) [17]. A systematic review has analyzed 
A. montana in eight randomized controlled trials (RCTs) 
from 1966 to 1997 [10]. Two of the included trials, one on the 
effect of A. montana on the delayed onset of muscle soreness 
(DOMS) and the other on the prevention of post-operative 
complications, showed a statistically significant result in favor 
of the homeopathic treatment. The other six trials did not 
demonstrate statistically significant differences, but some of 
these trials were not considered qualitatively adequate for a 
proper meta-analysis [10]. Other RCTs had conflictual data. 
Only one of the three RCTs on DOMS and none of the two on 
surgical patients showed statistically significant between-group 
differences, in particular, on the recovery after total abdominal 
hysterectomy and on the stripping of varicose veins [13,28-32]. 
In a double-blind, placebo-controlled clinical study involving 
patients undergoing prolonged venous perfusion, A. montana 
reduced pain symptoms, hyperemia, edema, and formation of 
hematomas [33]. A. montana treatment also slightly increased 
a number of coagulation factors and platelet aggregation.
In vitro studies are more promising. In fact, different authors 
have shown that helenalin, the most active component of 
A. montana, not only blocks the transcriptional NF-κB in T-cells, 
B-cells, and epithelial cells, but it also inhibits human neutrophil 
migration and chemotaxis and the activities of 5-lipoxygenase 
and leukotriene C4 synthase [34]. All these mechanisms 
are known to be associated with the induction of pain and 
inflammation, as observed in animal models of inflammatory 
pain [34,35]. However, these studies were conducted with 
pure helenalin rather than with plant extract and with much 
higher doses than those used here. A recent work carried out 
on human macrophage cells differentiated with interleukin-4 
demonstrated that homeopathic doses of A. montana stimulate 
the expression of genes involved in the repair of connective 
tissue and, in particular, fibronectin [36]. Given the importance 
of this protein to the adhesion, proliferation, and movement of 
cells (both epithelial and connective), this could be a further 
target at the cellular level of this plant’s action.
Undoubtedly, one as yet unsolved problem of homeopathy 
concerns the mechanism of action of dilutions so high that 
Table 4: Estimates of the mean difference in total volume 
collected by drainage during the study between the two treatment 
groups (Arnica–Placebo) by dataset
Dataset Model1 Variables Parameter 
estimate2
95% CI t‑value P value
ITT 1 Treatment −13.64 −138.51‑111.23 −0.22 0.83
2 Treatment −18.85 −129.87‑92.17 −0.34 0.73
3 Treatment −28.69 −138.27‑80.89 −0.53 0.60
PP 1 Treatment −94.40 −211.28‑22.48 −1.63 0.11
2 Treatment −90.28 −186.71‑6.14 −1.89 0.07
3 Treatment −106.28 −203.11‑−9.45 −2.22 0.03*
1Regression models are as follows: (1) Model 1: Treatment 
only, (2) Model 2: Treatment and volume collected on the day of 
the intervention, (3) Model 3: Treatment, volume collected the day 
of surgery, and patient’s weight, 2Mean difference in volume (mL) 
collected by drainage during the study between Arnica and placebo 
groups (Arnica–Placebo). *P<0.05. CI: Confidence interval, 
PP: Per‑protocol, ITT: Intention‑to‑treat
Figure 2: Duration of drainage (a) and time to drainage volume below 10 mL (b) per treatment (intention-to-treat and per-protocol datasets)
a
b
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the presumed active substances are often not detectable in 
molecular terms. Many laboratory studies that use homeopathic 
dilutions report dose-response curves that are non-linear and 
sometimes pseudo-sinusoidal, with peaks occurring at different 
dilutions, alternating with other inactive doses [37-39]. In 
relatively recent times, evidence has been found, especially 
in physicochemical studies, pointing to the presence of 
nanoparticles even in extremely high dilutions, or the formation 
of coherence domains among the molecules of the water–alcohol 
solvent, as predicted by quantum electrodynamics [40,41]. 
Although these findings fall outside the scope of the present 
work, if consolidated by further experimental studies, they 
might furnish a basis of plausibility to this complementary 
pharmacological approach.
The main limitations of the study were the relatively small 
sample, the analysis of post-operative recovery, which was limited 
only to 5 days, and the use of a high Korsakovian dilution which 
could have negatively impacted on the statistical significance of 
our findings. Observational studies with different Korsakovian 
dilutions could be useful to highlight any significant effect of 
A. montana and further validate these findings.
CONCLUSIONS
The scientific community often claims that homeopathy effects 
are not supported by rigorous clinical trials. This study, although 
reporting statistical significance only for some specific data 
settings, suggests a reduction in post-operative blood loss and 
seroma production in a group of women who underwent breast 
cancer surgery and treated with A. montana 1000 K.
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